Freyja

Freya Biosciences Announces $38 Million Funding in One of the Largest Series A Raises to Advance Women’s Reproductive Immunotherapies

Retrieved on: 
Tuesday, December 12, 2023

Freya Biosciences, a trans-Atlantic biotech company specializing in women's health, announced today a $38 million Series A financing – one of the largest raises to advance women’s reproductive immunotherapies.

Key Points: 
  • Freya Biosciences, a trans-Atlantic biotech company specializing in women's health, announced today a $38 million Series A financing – one of the largest raises to advance women’s reproductive immunotherapies.
  • “We are very excited to announce Freya’s Series A fundraise, with the support of this dedicated team of investors,” said Colleen Acosta, CEO of Freya Biosciences.
  • “Conditions that disproportionately and differently affect women have traditionally been underfunded in proportion to its burden on human health.
  • The funding will also advance Freya’s multi-omics data science platform, which includes deep microbiome sequencing and vast multiplexed immune biomarker profiling in human clinical samples.

Freya Systems Honored Consecutively With Drexel LeBow Analytics 50 Award

Retrieved on: 
Monday, July 17, 2023

MEDIA, Pa., July 17, 2023 (GLOBE NEWSWIRE) -- Freya Systems has been named a 2023 Drexel LeBow Analytics 50 Award honoree; this marks the second consecutive acknowledgement from the prestigious LeBow Center for Business Analytics at Drexel University’s LeBow College of Business.

Key Points: 
  • MEDIA, Pa., July 17, 2023 (GLOBE NEWSWIRE) -- Freya Systems has been named a 2023 Drexel LeBow Analytics 50 Award honoree; this marks the second consecutive acknowledgement from the prestigious LeBow Center for Business Analytics at Drexel University’s LeBow College of Business.
  • The Drexel LeBow Analytics 50 is a national recognition of analytics distinction honoring 50 organizations using analytics to solve business challenges.
  • The company’s Founder, Ben Johnson , expresses deep pride in the team's accomplishments, stating, "This recognition is a tremendous honor for the Freya Systems team.
  • For media connections with Freya Systems, please contact Cindi Sutera at [email protected] or 610-613-2773 at your convenience.

Freya Biosciences Announces Positive Topline Clinical Trial Results for FB101 in Women with Asymptomatic Vaginal Dysbiosis

Retrieved on: 
Tuesday, June 27, 2023

Freya Biosciences, a trans-Atlantic biotech company specializing in women's health, announces positive topline results from its first Phase 1 clinical study of its lead asset FB101, an investigational vaginal microbial immunotherapeutic.

Key Points: 
  • Freya Biosciences, a trans-Atlantic biotech company specializing in women's health, announces positive topline results from its first Phase 1 clinical study of its lead asset FB101, an investigational vaginal microbial immunotherapeutic.
  • These data allow the company to expand the clinical activities with FB101 to women seeking infertility treatment and undergoing in vitro fertilization (IVF).
  • The study, conducted in Europe, was a randomized, double-blind, placebo-controlled trial, evaluated the change in vaginal microbiome after vaginal administration of FB101 on three consecutive days in women with asymptomatic vaginal tract dysbiosis (NCT05114031).
  • Asymptomatic vaginal dysbiosis is a common finding in women undergoing IVF procedures and has detrimental implications on treatment success.

Dog detectives can sniff out protected great crested newts and reduce costly construction delays

Retrieved on: 
Monday, June 26, 2023

Great crested newts play crucial ecological roles.

Key Points: 
  • Great crested newts play crucial ecological roles.
  • But great crested newt populations are dwindling due to the widespread loss of suitable habitat, changes in farming practices and climate change.
  • Developments that may harm great crested newts can proceed only if suitable new habitats are made for them.
  • Great crested newts also tend to hide underground in mammal burrows and other inaccessible refuges, where they are hard to locate.

Dog detectives

    • We also tested how well Freya could detect the newts through two different soil types: clay and sand.
    • In some instances, we placed a vent within the soil to mimic a mammal burrow.
    • Freya accurately located all individual great crested newts across the entire range of tested distances (0.25 metres–2 metres).
    • The presence of moisture within clay soil may transport their odour to the surface more readily than in sandy soil.

Not so fast

    • Finding and relocating newts is costly and time-consuming at present, but a legal requirement prior to construction activities.
    • Great crested newts spend time both above and below the ground, as well as in inaccessible underground hiding places.
    • Using detection dogs to locate hidden great crested newts has the potential to protect this rare species and reduce costly construction delays.

Freya Systems Honored by Boeing for Outstanding Supplier Performance in 2022

Retrieved on: 
Monday, May 22, 2023

MEDIA, Pa., May 22, 2023 (GLOBE NEWSWIRE) -- Freya Systems is proud to announce that the company has been honored with a 2022 Supply Performance Achievement Certificate from Boeing.

Key Points: 
  • MEDIA, Pa., May 22, 2023 (GLOBE NEWSWIRE) -- Freya Systems is proud to announce that the company has been honored with a 2022 Supply Performance Achievement Certificate from Boeing.
  • This achievement recognizes superior performance of suppliers who provide Boeing with parts and services.
  • Less than 2% of the over 12,000 suppliers providing services to Boeing are honored each year, and Freya Systems is proud to be part of this distinguished group.
  • Ben Johnson, CEO of Freya Systems stated, “It’s an honor to be recognized by Boeing for the Supply Chain Performance Achievement; in 2022 only 241 out of 12,000 suppliers worldwide were recognized.

Freya Pharma Solutions Announces Advice from the FDA on its US Clinical Development Program of Lybrido™ for the treatment of Female Sexual Interest/Arousal Disorder

Retrieved on: 
Tuesday, May 9, 2023

After obtaining advice from the European Medicines Agency (EMA) in September 2022, Freya Pharma Solutions is currently preparing the confirmatory ALETTA trial as part of the clinical development program of Lybrido™ in Europe.

Key Points: 
  • After obtaining advice from the European Medicines Agency (EMA) in September 2022, Freya Pharma Solutions is currently preparing the confirmatory ALETTA trial as part of the clinical development program of Lybrido™ in Europe.
  • As a next step Freya has designed a clinical development program for the US in close collaboration with its Scientific Advisory Board consisting of leading experts in the field of FSD from the US and Europe, to prepare for a Marketing Authorization Application (MAA) of Lybrido™ in the US.
  • On Freya's request for advice, the FDA has now planned to provide a written response by 4 June 2023, where Freya's objective is to reach an agreement with the agency regarding the clinical development program of Lybrido™ in the US.
  • The ALETTA confirmatory clinical trial is planned to start soon in Europe, and we hope that with the advice from the FDA we can also soon start preparing clinical trials in the US.

Freya Pharma Solutions Announces Advice from the FDA on its US Clinical Development Program of Lybrido™ for the treatment of Female Sexual Interest/Arousal Disorder

Retrieved on: 
Tuesday, May 9, 2023

After obtaining advice from the European Medicines Agency (EMA) in September 2022, Freya Pharma Solutions is currently preparing the confirmatory ALETTA trial as part of the clinical development program of Lybrido™ in Europe.

Key Points: 
  • After obtaining advice from the European Medicines Agency (EMA) in September 2022, Freya Pharma Solutions is currently preparing the confirmatory ALETTA trial as part of the clinical development program of Lybrido™ in Europe.
  • As a next step Freya has designed a clinical development program for the US in close collaboration with its Scientific Advisory Board consisting of leading experts in the field of FSD from the US and Europe, to prepare for a Marketing Authorization Application (MAA) of Lybrido™ in the US.
  • On Freya's request for advice, the FDA has now planned to provide a written response by 4 June 2023, where Freya's objective is to reach an agreement with the agency regarding the clinical development program of Lybrido™ in the US.
  • The ALETTA confirmatory clinical trial is planned to start soon in Europe, and we hope that with the advice from the FDA we can also soon start preparing clinical trials in the US.

Freya Pharma Solutions appoints Christa van Kan as Director Clinical Operations, governing the company's upcoming confirmatory clinical development program using Lybrido™ against FSIAD

Retrieved on: 
Wednesday, March 8, 2023

Ms. van Kan brings more than 25 years of clinical operations and trial management experience to Freya Pharma Solutions.

Key Points: 
  • Ms. van Kan brings more than 25 years of clinical operations and trial management experience to Freya Pharma Solutions.
  • Marcel Wijma, CEO at Freya Pharma Solutions, said:
    "Christa possesses more than 25 years of experience in the contract research organization (CRO) industry.
  • As our newly appointed Director Clinical Operations, she will be responsible for driving the confirmatory clinical development of our FSD therapy platform.
  • Freya Pharma Solutions is currently preparing the clinical development program with several studies with Lybrido™ in Europe, to be followed later by trials in the United States.

Freya Pharma Solutions appoints Christa van Kan as Director Clinical Operations, governing the company's upcoming confirmatory clinical development program using Lybrido™ against FSIAD

Retrieved on: 
Wednesday, March 8, 2023

Ms. van Kan brings more than 25 years of clinical operations and trial management experience to Freya Pharma Solutions.

Key Points: 
  • Ms. van Kan brings more than 25 years of clinical operations and trial management experience to Freya Pharma Solutions.
  • Marcel Wijma, CEO at Freya Pharma Solutions, said:
    "Christa possesses more than 25 years of experience in the contract research organization (CRO) industry.
  • As our newly appointed Director Clinical Operations, she will be responsible for driving the confirmatory clinical development of our FSD therapy platform.
  • Freya Pharma Solutions is currently preparing the clinical development program with several studies with Lybrido™ in Europe, to be followed later by trials in the United States.

Freya Pharma Solutions appoints Nicole Hijnen as President of the Board, overseeing the company's upcoming clinical development program with Lybrido™ against FSIAD

Retrieved on: 
Thursday, February 2, 2023

Her appointment comes in a year where Freya is rolling out its final clinical development program, starting with the confirmatory ALETTA clinical trial with Lybrido™ in premenopausal women with acquired FSIAD.

Key Points: 
  • Her appointment comes in a year where Freya is rolling out its final clinical development program, starting with the confirmatory ALETTA clinical trial with Lybrido™ in premenopausal women with acquired FSIAD.
  • Marcel Wijma, CEO at Freya Pharma Solutions said:
    "We are very pleased to have Nicole join Freya as President of our Board as we are on the brink of commencing our confirmatory clinical trial with our promising compound Lybrido™ against FSIAD.
  • She brings exactly the right blend of academic and operational healthtech experience to help guide Freya to the next phase.
  • Nicole Hijnen, PhD, new President of Freya's Board, commented:
    "I am excited to be joining Freya as President of the Board.